Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeff Allen

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
CNS Spectrums|April 15, 2014
Attitudes toward borderline personality disorder: a survey of 706 mental health cliniciansDonald W Black, Bruce Pfohl, Nancee Blum, et al.
Science Translational Medicine|August 2, 2013
Breaking a vicious cycleDaniel F Hayes, Jeff Allen, Carolyn Compton, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2018
Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility CriteriaPhilip Bonomi, Gideon Blumenthal, Andrea Stern Ferris, et al.
European Journal of Neurology|November 28, 2023
Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated doseAmro M Stino, Naresh Bumma, Rachel Smith, et al.
Journal for Immunotherapy of Cancer|May 19, 2019
The promise of Immuno-oncology: implications for defining the value of cancer treatmentHoward L Kaufman, Michael B Atkins, Prasun Subedi, et al.
Cytotherapy|March 23, 2020
Accelerating the development of innovative cellular therapy products for the treatment of cancerMark D Stewart, Anne Keane, Lisa H Butterfield, et al.
Critical Reviews in Oncology/Hematology|October 9, 2020
International liquid biopsy standardization alliance white paperDana Connors, Jeff Allen, J D Alvarez, et al.
JCO Clinical Cancer Informatics|July 24, 2019
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung CancerMark Stewart, Andrew D Norden, Nancy Dreyer, et al.
Journal for Immunotherapy of Cancer|September 22, 2025
Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapyHillary S Andrews, Nevine Zariffa, Katherine K Nishimura, et al.
Clinical Pharmacology and Therapeutics|October 16, 2021
Real-world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research PilotLaura Lasiter, Olga Tymejczyk, Elizabeth Garrett-Mayer, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
CNS Spectrums|April 15, 2014
Attitudes toward borderline personality disorder: a survey of 706 mental health cliniciansDonald W Black, Bruce Pfohl, Nancee Blum, et al.
Science Translational Medicine|August 2, 2013
Breaking a vicious cycleDaniel F Hayes, Jeff Allen, Carolyn Compton, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2018
Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility CriteriaPhilip Bonomi, Gideon Blumenthal, Andrea Stern Ferris, et al.
European Journal of Neurology|November 28, 2023
Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated doseAmro M Stino, Naresh Bumma, Rachel Smith, et al.
Journal for Immunotherapy of Cancer|May 19, 2019
The promise of Immuno-oncology: implications for defining the value of cancer treatmentHoward L Kaufman, Michael B Atkins, Prasun Subedi, et al.
Cytotherapy|March 23, 2020
Accelerating the development of innovative cellular therapy products for the treatment of cancerMark D Stewart, Anne Keane, Lisa H Butterfield, et al.
Critical Reviews in Oncology/Hematology|October 9, 2020
International liquid biopsy standardization alliance white paperDana Connors, Jeff Allen, J D Alvarez, et al.
JCO Clinical Cancer Informatics|July 24, 2019
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung CancerMark Stewart, Andrew D Norden, Nancy Dreyer, et al.
Journal for Immunotherapy of Cancer|September 22, 2025
Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapyHillary S Andrews, Nevine Zariffa, Katherine K Nishimura, et al.
Clinical Pharmacology and Therapeutics|October 16, 2021
Real-world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research PilotLaura Lasiter, Olga Tymejczyk, Elizabeth Garrett-Mayer, et al.
Pageof 10